Serous Retinal Detachments Complicating Interferon-α and Ribavirin Treatment in Patients with Hepatitis C
Published: March 2011
Giulio Modorati, Federico Di Matteo, Elisabetta Miserocchi, Annalisa Colucci, Francesco Bandello Department of Ophthalmology, University Vita-Salute, Scientific Institute San Raffaele, Milan, Italy Address of Corresponding Author Case Rep Ophthalmol 2011;2:105-110 (DOI: 10.1159/000326747)
Article (PDF 105 KB)
To report the cases of two patients with chronic hepatitis C infection showing serous retinal detachments similar to Vogt-Koyanagi-Harada (VKH) disease.
We reviewed the clinical records of two patients who were diagnosed with VKH-like disease during combined interferon-α (IFNα) and ribavirin treatment.Results: Interruption of IFNα and ribavirin treatment in association with oral corticosteroids resulted in a favorable visual outcome in the case of diffuse retinal detachment (case 1). On the contrary, visual acuity did not improve when late cicatricial stage disease was already present (case 2).
There is increasing evidence of a link between hepatitis C virus infection treated with pegylated IFNα-2b and the development of VKH-like disease. Knowing the potential side effects of IFNα and ribavirin administration is fundamentally important, as is the need to closely follow up those patients that need to undergo this treatment.
Vogt-Koyanagi-Harada (VKH) disease, also known as uveo meningitic syndrome, is a rare idiopathic multi system autoimmune granulomatous disorder affecting the eyes, meninges, auditory system and skin. The disease is thought to be due to an autoimmune Th1-mediated response to a melanocyte-associated antigen , but the initiation mechanism and development of the exact process remain poorly understood.
Recent reports suggest a link between hepatitis C virus (HCV) infection and/or its treatment and the development of bilateral uveitis that is virtually identical to VKH disease. We present two cases of VKH-like disease in patients treated with pegylated interferon-α (IFNα) and ribavirin for chronic hepatitis C.
A 61-year-old woman contracted HCV in 2006 following a blood transfusion performed during a colectomy for adenocarcinoma. The patient’s past medical history was relevant only for type I diabetes mellitus controlled with insulin therapy. Because of histological damage at liver biopsy, she was prescribed pegylated IFNα and ribavirin treatment from October 2006. After 3 months, the patient was referred to a hepatologist because of sudden vision loss in both eyes. The physician suspected an interferon-related side effect and immediately interrupted the treatment. Upon presentation at our Ocular Immunology and Uveitis Service, the patient’s best-corrected visual acuity was hand motion inthe right eye and 20/400 in the left eye. The anterior segment examination was normal and intraocular pressure was 10 mm Hg in both eyes. The fundus examination showed diffuse bilateral serous retinal detachment (fig. 1). No auditory or neurological symptoms were noted, nor vitiligo, alopecia, orpoliosis. Based on the revised diagnostic criteria for VKH we diagnosed ‘probable’ VKH disease and prescribed treatment with oral prednisone 25 mg/die; the patient recovered to 20/25 in the right eye andto 20/20 in the left eye.
A 36-year-old man with HCV since 2004 was taking pegylated IFNα and ribavirin during the same period. He also suffered from celiac disease. After 6 months of treatment, he referred bilateral sudden vision loss to his ophthalmologist and was treated with 12.5 mg oral prednisone per day without visual improvement. The patient was referred to our Ocular Immunology and Uveitis Service 15 months after the onset of initial symptoms for a second diagnostic and therapeutic opinion. At presentation, best corrected visual acuity was 20/200 in the right eye and 20/40 in the left eye. No neurological or auditory signs were noted, nor were vitiligo, poliosis or alopecia. The anterior segment revealed a marked posterior cortical cataract in the right eye and an initial posterior subcapsular cataract in the left eye. We noted bilateral nummular chorioretinal depigmented scars and retinal pigment epithelium clumping and migration compatible with late cicatricial stage probable VKH disease (fig. 2).
Previous fluoresce in angiograms showed multiple pinpoint hyper fluorescence at the level of the pigment epithelium and diffuse exudative retinal detachments in both eyes. Despite discontinuation of IFNα and ribavirin visual acuity did not improve.
A causal effect between IFNα treatment for HCV infection and VKH disease has not yet been proven. The exact etiology of VKH itself remains unclear. VKH syndrome is possibly caused by a T cell-mediated autoimmune reaction against proteins related with choroidal melanocytes. The fact that the disease prevalence varies considerably among populations and that it commonly affects people with more pigmented skin and a certain HLA (human leukocyte antigen) predisposition highlights the importance of individual genetic predisposition for the development of VKH disease.
However, the autoimmune reaction needs to be initiated by a triggering agent. Epstein-Barr or cytomegalovirus infections have been proposed as initiating factors. The infection may lead to the production of auto reactive antibodies through a process of molecular mimicry between viral and melanocyte-related antigens .
The immunogenicity of IFNα in ocular tissue has been known since 1997 when a possible role in the development of Behcet’s disease, another autoimmune disorder in which T cell-mediated activation is thought to play a major role, was suggested.
Furthermore, interferon and ribavirin can induce a Th1 response and modify the expression of MHC class II antigens, both of which are associated with the development of VKH disease. Therefore, despite the lack of evidence of a causal effect, IFNα and ribavirin might be involved in both the initiation of the autoimmune process and the induction of a higher susceptibility in developing VKH syndrome.
The association between VKH-like syndrome and interferon treatment for hepatitis C was first suggested in 2003 . Since then, seven other cases of HCV-positive patients presenting a VKH-like disease after IFNα treatment have been reported in the literature [3–5].
Most of the reported cases (table 1) show signs of systemic involvement such as skin lesions, auditory or neurologic symptoms in association with serous retinal detachment, which is one of the hallmarks of VKH disease.
Nevertheless, our cases highlight the importance of including serous retinal detachment without systemic signs in suspecting VKH-like disease in patients under IFNα and ribavirin treatment for hepatitis C.
Despite the widespread use of interferon and ribavirin for the treatment of hepatitis C,the small number of published cases of VKH-like disease following IFNα treatment shows that ocular immunological side effects are rare. However, IFNα may cause other more common significant side effects, including retinal vascular disorders, ischemic optic neuropathies, neo vascular glaucoma and ‘specific IFNα-related retinopathy,’ i.e. retinopathy characterized by retinal hemorrhages, micro aneurysms, and cotton-wool spots.
The presented cases emphasize the importance of early recognition and prompt adequate ophthalmological therapy in the presence of a VKH-like disease associated withIFN treatment. Discontinuation of IFN and ribavirin treatment in association with oral corti costeroids might result in a favorable visual outcome in the case of diffuse retinal detachment (case 1). Conversely, visual recovery is usually poor when late cicatricial stage disease is already present (case 2). If not promptly recognized, IFNα-related effects may lead to chronic bilateral severe vision loss. Therefore, it is of fundamental importance to recognize the potential side effects of IFNα and ribavirin administration, and to closely follow up patients if treatment needs to be continued.
The authors wish to thank Michael John, Professor of Applied English at the Vita-Salute San RaffaeleUniversity, for the English language editing of this manuscript.Disclosure StatementNone of the authors has any financial interests concerning procedures nor drugs cited in this manuscript.
Copyright © 2011 S. Karger AG, Basel Author Contacts Giulio Modorati, MDDepartment of Ophthalmology, University Vita-SaluteSan Raffaele Scientific InstituteIT–20132 Milan (Italy)Tel. +39 02 2643 3512, E-Mail email@example.com Article Information Published online: March 12, 2011 Number of Print Pages : 6 Number of Figures : 2, Number of Tables : 1,
- Newly Diagnosed
- All FDA Approved Drugs To Treat Hepatitis C
- 2017-HCV Genotypes/Treatment
- Epclusa® (Sofosbuvir/Velpatasvir)
- Harvoni® (Ledipasvir/Sofosbuvir)
- VIEKIRA XR/VIEKIRA Pak
- Not FDA Approved - Sofosbuvir/Velpatasvir/Voxilaprevir
- Not FDA Approved - Glecaprevir/Pibrentasvir (G/P)
- NOT FDA Approved - MK3 (MK-3682/grazoprevir/ruzasvir1)
- Cure - Achieving sustained virologic response (SVR) in hepatitis C
- FibroScan® Understanding The Results
- Is There A Natural Way To Improve Liver Fibrosis?
- Staging Cirrhosis